| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1023112525 |
| P356 | DOI | 10.1186/S12866-015-0400-1 |
| P932 | PMC publication ID | 4391109 |
| P698 | PubMed publication ID | 25888448 |
| P5875 | ResearchGate publication ID | 274732737 |
| P50 | author | Harry Sokol | Q56382889 |
| Rebeca Martín | Q57061138 | ||
| Florian Chain | Q58227783 | ||
| Sylvie Miquel | Q85069522 | ||
| Elena F. Verdu | Q91760320 | ||
| Philippe Langella | Q114447036 | ||
| P2093 | author name string | Jun Lu | |
| Jennifer Jury | |||
| Premysl Bercik | |||
| Jane M Natividad | |||
| Luis G Bermúdez-Humarán | |||
| Vassilia Theodorou | |||
| P2860 | cites work | Pathogenic Factors Involved in the Development of Irritable Bowel Syndrome: Focus on a Microbial Role | Q37799433 |
| The intestinal microbiota and chronic disorders of the gut. | Q37918323 | ||
| The shifting interface between IBS and IBD. | Q37945956 | ||
| Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria. | Q37973803 | ||
| Microbes and the gut-brain axis | Q37992100 | ||
| Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis | Q38038777 | ||
| Th22 and related cytokines in inflammatory and autoimmune diseases | Q38068964 | ||
| Sealing the broken barrier in IBD: intestinal permeability, epithelial cells and junctions | Q38141243 | ||
| The meaning of low-grade inflammation in clinically quiescent inflammatory bowel disease | Q38210384 | ||
| Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats | Q42177644 | ||
| Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis | Q42482132 | ||
| Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function | Q42989196 | ||
| Role of cytokines in inflammatory bowel disease | Q43065113 | ||
| Analysis of real-time serotonin (5-HT) availability during experimental colitis in mouse. | Q43216735 | ||
| Faecalibacterium prausnitzii supernatant improves intestinal barrier function in mice DSS colitis. | Q44822234 | ||
| Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis | Q45897347 | ||
| Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. | Q46118752 | ||
| Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. | Q47837794 | ||
| IFN-gamma and TNF-alpha decrease serotonin transporter function and expression in Caco2 cells. | Q51093833 | ||
| Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. | Q54576196 | ||
| Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid | Q70802401 | ||
| Some immunomodulatory effects of probiotic bacteria might be due to porcine neutrophil elastase inhibitor, a serpin present in MRS broth | Q82919350 | ||
| Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse | Q83343544 | ||
| Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome | Q84705462 | ||
| The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models | Q87087790 | ||
| The NIH Human Microbiome Project | Q24642619 | ||
| Irritable bowel syndrome | Q24670113 | ||
| Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 | ||
| Towards the human intestinal microbiota phylogenetic core | Q28251918 | ||
| Faecalibacterium prausnitzii and human intestinal health | Q28294074 | ||
| Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients | Q29614261 | ||
| Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease | Q30519492 | ||
| Host responses to intestinal microbial antigens in gluten-sensitive mice | Q33489534 | ||
| The microbiome in inflammatory bowel disease: current status and the future ahead | Q33664898 | ||
| Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors | Q34115993 | ||
| Regulation of intestinal epithelial permeability by tight junctions. | Q34287155 | ||
| Gut hormones: emerging role in immune activation and inflammation. | Q34618925 | ||
| Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent | Q34732850 | ||
| Inflammatory bowel diseases: a dysfunction of brain-gut interactions? | Q34836506 | ||
| Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome | Q34992347 | ||
| Gut ecosystem: how microbes help us. | Q35105266 | ||
| Irritable bowel syndrome, gut microbiota and probiotics. | Q35161373 | ||
| Inflammatory bowel disease and irritable bowel syndrome: similarities and differences | Q35165625 | ||
| Is the irritable gut an inflamed gut? | Q35532162 | ||
| Flagellin suppresses epithelial apoptosis and limits disease during enteric infection | Q35607301 | ||
| Regulation of inflammation by interleukin-4: a review of "alternatives" | Q36232198 | ||
| Inflammation as a cause of functional bowel disorders. | Q36304518 | ||
| Sensitization to gliadin induces moderate enteropathy and insulitis in nonobese diabetic-DQ8 mice | Q36383508 | ||
| Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. | Q36711467 | ||
| New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. | Q36724324 | ||
| Differential role of lipocalin 2 during immune complex-mediated acute and chronic inflammation in mice | Q36745368 | ||
| Mechanism of cytokine modulation of epithelial tight junction barrier | Q37047106 | ||
| Analysis of bacterial bowel communities of IBD patients: what has it revealed? | Q37084765 | ||
| Serotonin and GI clinical disorders. | Q37237965 | ||
| Cytokine regulation of tight junctions | Q37308566 | ||
| The tight junction in inflammatory disease: communication breakdown | Q37457219 | ||
| Irritable bowel syndrome: towards biomarker identification | Q37610606 | ||
| Diagnosis and management of IBS. | Q37796599 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | inflammation | Q101991 |
| Faecalibacterium prausnitzii | Q3738296 | ||
| murine model | Q122890741 | ||
| P304 | page(s) | 67 | |
| P577 | publication date | 2015-03-21 | |
| P1433 | published in | BMC Microbiology | Q15759430 |
| P1476 | title | Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model | |
| P478 | volume | 15 |
| Q52595193 | A Versatile New Model of Chemically Induced Chronic Colitis Using an Outbred Murine Strain. |
| Q58758724 | Alterations in the Abundance and Co-occurrence of and in the Colonic Mucosa of Inflammatory Bowel Disease Subjects |
| Q37678345 | Altered intestinal microbiota in patients with chronic pancreatitis: implications in diabetes and metabolic abnormalities |
| Q89493771 | Antidepressive Mechanisms of Probiotics and Their Therapeutic Potential |
| Q41203961 | Bacteriophages as potential new mammalian pathogens. |
| Q26742179 | Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut |
| Q36875133 | Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice |
| Q57114614 | Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice |
| Q60950163 | Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes |
| Q28828501 | Causality of small and large intestinal microbiota in weight regulation and insulin resistance |
| Q38600883 | Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes. |
| Q96170645 | Dendrobium officinale Kimura et Migo and American ginseng mixture: A Chinese herbal formulation for gut microbiota modulation |
| Q35913240 | Different Effects of Three Selected Lactobacillus Strains in Dextran Sulfate Sodium-Induced Colitis in BALB/c Mice |
| Q58759764 | Differential effects of dietary fibres on colonic barrier function in elderly individuals with gastrointestinal symptoms |
| Q37185179 | Ecological robustness of the gut microbiota in response to ingestion of transient food-borne microbes |
| Q91793896 | Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota |
| Q47888594 | Effects of Supernatants from Escherichia coli Nissle 1917 and Faecalibacterium prausnitzii on Intestinal Epithelial Cells and a Rat Model of 5-Fluorouracil-Induced Mucositis |
| Q37660757 | Enterotype May Drive the Dietary-Associated Cardiometabolic Risk Factors |
| Q42695131 | Faecal and mucosal microbiota in patients with functional gastrointestinal disorders: Correlation with toll-like receptor 2/toll-like receptor 4 expression |
| Q90019547 | Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression |
| Q39065664 | Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics |
| Q57177955 | Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome |
| Q35935129 | Gut microbiota, obesity and diabetes. |
| Q38643980 | Heart failure is associated with depletion of core intestinal microbiota |
| Q38827085 | Identification of novel anti-inflammatory probiotic strains isolated from pulque. |
| Q53688957 | Increased gut permeability in cancer cachexia: mechanisms and clinical relevance. |
| Q89553143 | Increasing incidence of inflammatory bowel disease in children and adolescents: the significance of the environmental factors |
| Q46242554 | Influence of Microbiota on Intestinal Immune System in Ulcerative Colitis and Its Intervention. |
| Q40974571 | Intestinal Anti-inflammatory Effects of Outer Membrane Vesicles from Escherichia coli Nissle 1917 in DSS-Experimental Colitis in Mice |
| Q47389435 | Lactobacillus plantarum HNU082-derived improvements in the intestinal microbiome prevent the development of hyperlipidaemia. |
| Q36191384 | Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice |
| Q44995961 | Low Microbial Diversity and Abnormal Microbial Succession Is Associated with Necrotizing Enterocolitis in Preterm Infants. |
| Q37617472 | Microbial Anti-Inflammatory Molecule (MAM) from Faecalibacterium prausnitzii Shows a Protective Effect on DNBS and DSS-Induced Colitis Model in Mice through Inhibition of NF-κB Pathway. |
| Q90079839 | Modulation of the intestinal microbiota and the metabolites produced by the administration of ice cream and a dietary supplement containing the same probiotics |
| Q26774703 | Molecular Players Involved in the Interaction Between Beneficial Bacteria and the Immune System |
| Q28603476 | Oral Administration of Faecalibacterium prausnitzii Decreased the Incidence of Severe Diarrhea and Related Mortality Rate and Increased Weight Gain in Preweaned Dairy Heifers |
| Q42352756 | Outer Membrane Vesicles and Soluble Factors Released by Probiotic Escherichia coli Nissle 1917 and Commensal ECOR63 Enhance Barrier Function by Regulating Expression of Tight Junction Proteins in Intestinal Epithelial Cells |
| Q43594513 | Probiotics: a proactive approach to health. A symposium report |
| Q46271336 | Protease-Mediated Suppression of DRG Neuron Excitability by Commensal Bacteria. |
| Q61984893 | RETRACTED: Analysis of gut microbiota in long-lived older adults and their relatives: a gradual change with ageing |
| Q48109846 | Real friends: Faecalibacterium prausnitzii supports mucosal immune homeostasis. |
| Q28072085 | Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome |
| Q55198895 | Searching for the Bacterial Effector: The Example of the Multi-Skilled Commensal Bacterium Faecalibacterium prausnitzii. |
| Q55400264 | Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. |
| Q64997664 | The Immunomodulatory Properties of Extracellular Vesicles Derived from Probiotics: A Novel Approach for the Management of Gastrointestinal Diseases. |
| Q90224285 | The Potential Impact of Probiotics on the Gut Microbiome of Athletes |
| Q57174271 | The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function and Alleviating Inflammation |
| Q59137716 | The Probiotic Effectiveness in Preventing Experimental Colitis Is Correlated With Host Gut Microbiota |
| Q64097633 | The potential probiotic Lactobacillus rhamnosus CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response |
| Q90463869 | The role of the microbiota in infectious diseases |
| Q40084224 | Using murine colitis models to analyze probiotics-host interactions. |
Search more.